Myeloid growth factors clinical practice guidelines in oncology

Jeffrey Crawford, Betsy Althaus, James Olen Armitage, Douglas W. Blayney, Spero Cataland, David C. Dale, George D. Demetri, James Foran, Mark L. Heaney, Sally Htoy, Dwight D. Kloth, Gary H. Lyman, Laura Michaud, Susannah Motl, Saroj Vadhan-Raj, Michael K. Wong

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs.

Original languageEnglish (US)
Pages (from-to)540-555
Number of pages16
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume3
Issue number4
StatePublished - Jul 1 2005

Fingerprint

Practice Guidelines
Colony-Stimulating Factors
Intercellular Signaling Peptides and Proteins
Neutropenia
Drug Therapy
Cost-Benefit Analysis
Guidelines
Morbidity
Costs and Cost Analysis
Mortality
Neoplasms

Keywords

  • Chemotherapy
  • Colony-stimulating factors
  • Fever
  • Morbidity
  • Myeloid growth factors
  • NCCN Clinical Practice Guidelines
  • Neutropenia
  • Toxicity

ASJC Scopus subject areas

  • Oncology

Cite this

Crawford, J., Althaus, B., Armitage, J. O., Blayney, D. W., Cataland, S., Dale, D. C., ... Wong, M. K. (2005). Myeloid growth factors clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 3(4), 540-555.

Myeloid growth factors clinical practice guidelines in oncology. / Crawford, Jeffrey; Althaus, Betsy; Armitage, James Olen; Blayney, Douglas W.; Cataland, Spero; Dale, David C.; Demetri, George D.; Foran, James; Heaney, Mark L.; Htoy, Sally; Kloth, Dwight D.; Lyman, Gary H.; Michaud, Laura; Motl, Susannah; Vadhan-Raj, Saroj; Wong, Michael K.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 3, No. 4, 01.07.2005, p. 540-555.

Research output: Contribution to journalReview article

Crawford, J, Althaus, B, Armitage, JO, Blayney, DW, Cataland, S, Dale, DC, Demetri, GD, Foran, J, Heaney, ML, Htoy, S, Kloth, DD, Lyman, GH, Michaud, L, Motl, S, Vadhan-Raj, S & Wong, MK 2005, 'Myeloid growth factors clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 3, no. 4, pp. 540-555.
Crawford J, Althaus B, Armitage JO, Blayney DW, Cataland S, Dale DC et al. Myeloid growth factors clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2005 Jul 1;3(4):540-555.
Crawford, Jeffrey ; Althaus, Betsy ; Armitage, James Olen ; Blayney, Douglas W. ; Cataland, Spero ; Dale, David C. ; Demetri, George D. ; Foran, James ; Heaney, Mark L. ; Htoy, Sally ; Kloth, Dwight D. ; Lyman, Gary H. ; Michaud, Laura ; Motl, Susannah ; Vadhan-Raj, Saroj ; Wong, Michael K. / Myeloid growth factors clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2005 ; Vol. 3, No. 4. pp. 540-555.
@article{7c2eeed9a3dc4cb1a79b6fd53159d9c2,
title = "Myeloid growth factors clinical practice guidelines in oncology",
abstract = "Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs.",
keywords = "Chemotherapy, Colony-stimulating factors, Fever, Morbidity, Myeloid growth factors, NCCN Clinical Practice Guidelines, Neutropenia, Toxicity",
author = "Jeffrey Crawford and Betsy Althaus and Armitage, {James Olen} and Blayney, {Douglas W.} and Spero Cataland and Dale, {David C.} and Demetri, {George D.} and James Foran and Heaney, {Mark L.} and Sally Htoy and Kloth, {Dwight D.} and Lyman, {Gary H.} and Laura Michaud and Susannah Motl and Saroj Vadhan-Raj and Wong, {Michael K.}",
year = "2005",
month = "7",
day = "1",
language = "English (US)",
volume = "3",
pages = "540--555",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Myeloid growth factors clinical practice guidelines in oncology

AU - Crawford, Jeffrey

AU - Althaus, Betsy

AU - Armitage, James Olen

AU - Blayney, Douglas W.

AU - Cataland, Spero

AU - Dale, David C.

AU - Demetri, George D.

AU - Foran, James

AU - Heaney, Mark L.

AU - Htoy, Sally

AU - Kloth, Dwight D.

AU - Lyman, Gary H.

AU - Michaud, Laura

AU - Motl, Susannah

AU - Vadhan-Raj, Saroj

AU - Wong, Michael K.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs.

AB - Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs.

KW - Chemotherapy

KW - Colony-stimulating factors

KW - Fever

KW - Morbidity

KW - Myeloid growth factors

KW - NCCN Clinical Practice Guidelines

KW - Neutropenia

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=27744548284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744548284&partnerID=8YFLogxK

M3 - Review article

C2 - 16038645

AN - SCOPUS:27744548284

VL - 3

SP - 540

EP - 555

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 4

ER -